PMID- 24411528
OWN - NLM
STAT- MEDLINE
DCOM- 20140923
LR  - 20211021
IS  - 1573-2509 (Electronic)
IS  - 0920-9964 (Print)
IS  - 0920-9964 (Linking)
VI  - 152
IP  - 2-3
DP  - 2014 Feb
TI  - BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia 
      occurrence and severity: a meta-analysis.
PG  - 365-72
LID - S0920-9964(13)00686-5 [pii]
LID - 10.1016/j.schres.2013.12.011 [doi]
AB  - BACKGROUND: Tardive dyskinesia (TD) is a serious long-term consequence of 
      antipsychotic treatment. Since brain-derived neurotrophic factor (BDNF) has 
      potent neurotrophic activity, genetic alterations in the BDNF gene may affect 
      antipsychotic-induced TD. METHODS: Searching PubMed and Web of Science until 
      05/31/13, we conducted a systematic review and a meta-analysis of the effects of 
      BDNF Val66Met polymorphism on antipsychotic-induced TD. Pooled odds ratio was 
      calculated to assess the effects of BDNF Val66Met polymorphism on TD occurrence. 
      Additionally, pooled standardized mean differences (Hedges' g) were calculated to 
      assess the effects on Abnormal Involuntary Movement Scale (AIMS) total score. 
      RESULTS: Out of 699 potentially eligible hits, 6 studies (N=1740, mean 
      age=46.0+/-10.4years; males=73.1%; Asians=80.5%, Caucasians=19.5%; 
      schizophrenia=96.2%) were included in this meta-analysis. Pooling data from all 
      studies, no significant associations were found between BDNF Val66Met 
      polymorphism and TD (p=0.82) or AIMS total scores (p=0.11). However, in studies 
      including only Caucasians (n=339), Met allele carriers had significantly higher 
      AIMS total scores (Hedges' g=0.253, 95% confidence interval=0.030 to 0.476, 
      p=0.026) and non-significantly higher TD occurrence (p=0.127). Conversely, there 
      was no association between BDNF and AIMS scores (p=0.57) or TD (p=0.65) in 
      Asians. CONCLUSION: Although there was no significant association between BDNF 
      Val66Met polymorphism and TD or AIMS scores across all patients, our results 
      suggest that BDNF Val66Met polymorphism affects severity and, possibly, TD 
      development in Caucasians. Since the number of studies and patients was still 
      small, additional data are needed to confirm genotype-racial interactions. 
      Furthermore, BDNF enhancing treatments for TD may require further study, 
      especially in Caucasians.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Miura, Itaru
AU  - Miura I
AD  - The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System, Glen Oaks, NY, USA; Department of Neuropsychiatry, 
      Fukushima Medical University School of Medicine, Fukushima, Japan.
FAU - Zhang, Jian-Ping
AU  - Zhang JP
AD  - The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System, Glen Oaks, NY, USA; Hofstra North Shore LIJ School of 
      Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, 
      Manhasset, NY, USA.
FAU - Nitta, Masahiro
AU  - Nitta M
AD  - The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System, Glen Oaks, NY, USA; Dainippon Sumitomo Pharma Co., Ltd., 
      Tokyo, Japan.
FAU - Lencz, Todd
AU  - Lencz T
AD  - The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System, Glen Oaks, NY, USA; Hofstra North Shore LIJ School of 
      Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, 
      Manhasset, NY, USA; Albert Einstein College of Medicine, Bronx, NY, USA.
FAU - Kane, John M
AU  - Kane JM
AD  - The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System, Glen Oaks, NY, USA; Hofstra North Shore LIJ School of 
      Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, 
      Manhasset, NY, USA; Albert Einstein College of Medicine, Bronx, NY, USA.
FAU - Malhotra, Anil K
AU  - Malhotra AK
AD  - The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System, Glen Oaks, NY, USA; Hofstra North Shore LIJ School of 
      Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, 
      Manhasset, NY, USA; Albert Einstein College of Medicine, Bronx, NY, USA.
FAU - Yabe, Hirooki
AU  - Yabe H
AD  - Department of Neuropsychiatry, Fukushima Medical University School of Medicine, 
      Fukushima, Japan.
FAU - Correll, Christoph U
AU  - Correll CU
AD  - The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System, Glen Oaks, NY, USA; Hofstra North Shore LIJ School of 
      Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, 
      Manhasset, NY, USA; Albert Einstein College of Medicine, Bronx, NY, USA. 
      Electronic address: ccorrell@lij.edu.
LA  - eng
GR  - K23 MH097108/MH/NIMH NIH HHS/United States
GR  - P30 MH090590/MH/NIMH NIH HHS/United States
GR  - P30MH090590/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Systematic Review
DEP - 20140107
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - AE28F7PNPL (Methionine)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*adverse effects
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Databases, Bibliographic/statistics & numerical data
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Methionine/genetics
MH  - Middle Aged
MH  - Movement Disorders/ethnology/*etiology/*genetics
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Schizophrenia/drug therapy/ethnology
MH  - Severity of Illness Index
MH  - Valine/genetics
PMC - PMC4010225
MID - NIHMS552784
OTO - NOTNLM
OT  - AIMS
OT  - BDNF
OT  - Genotype
OT  - Race
OT  - Schizophrenia
OT  - Tardive dyskinesia
COIS- Conflicts of interest: Dr. Yabe has nothing to disclose.
EDAT- 2014/01/15 06:00
MHDA- 2014/09/24 06:00
PMCR- 2015/02/01
CRDT- 2014/01/14 06:00
PHST- 2013/10/29 00:00 [received]
PHST- 2013/12/13 00:00 [revised]
PHST- 2013/12/18 00:00 [accepted]
PHST- 2014/01/14 06:00 [entrez]
PHST- 2014/01/15 06:00 [pubmed]
PHST- 2014/09/24 06:00 [medline]
PHST- 2015/02/01 00:00 [pmc-release]
AID - S0920-9964(13)00686-5 [pii]
AID - 10.1016/j.schres.2013.12.011 [doi]
PST - ppublish
SO  - Schizophr Res. 2014 Feb;152(2-3):365-72. doi: 10.1016/j.schres.2013.12.011. Epub 
      2014 Jan 7.